Modeling cancer glycolysis.
Most cancer cells exhibit an accelerated glycolysis rate compared to normal cells. This metabolic change is associated with the over-expression of all the pathway enzymes and transporters (as induced by HIF-1α and other oncogenes), and with the expression of hexokinase (HK) and phosphofructokinase type 1 (PFK-1) isoenzymes with different regulatory properties. Hence, a control distribution of tumor glycolysis, modified from that observed in normal cells, can be expected. To define the control distribution and to understand the underlying control mechanisms, kinetic models of glycolysis of rodent AS-30D hepatoma and human cervix HeLa cells were constructed with experimental data obtained here for each pathway step (enzyme kinetics; steady-state pathway metabolite concentrations and fluxes). The models predicted with high accuracy the fluxes and metabolite concentrations found in living cancer cells under physiological O(2) and glucose concentrations as well as under hypoxic and hypoglycemic conditions prevailing during tumor progression. The results indicated that HK≥HPI>GLUT in AS-30D whereas glycogen degradation≥GLUT>HK in HeLa were the main flux- and ATP concentration-control steps. Modeling also revealed that, in order to diminish the glycolytic flux or the ATP concentration by 50%, it was required to decrease GLUT or HK or HPI by 76% (AS-30D), and GLUT or glycogen degradation by 87-99% (HeLa), or decreasing simultaneously the mentioned steps by 47%. Thus, these proteins are proposed to be the foremost therapeutic targets because their simultaneous inhibition will have greater antagonistic effects on tumor energy metabolism than inhibition of all other glycolytic, non-controlling, enzymes.
Departamento de Bioquímica, Instituto Nacional de Cardiología, México D.F. 14080, México.
Alvaro
A
Marín-Hernández
Juan Carlos
JC
Gallardo-Pérez
Sara
S
Rodríguez-Enríquez
Rusely
R
Encalada
Rafael
R
Moreno-Sánchez
Emma
E
Saavedra
D001692:Biological Transport / Q000502:physiology; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000473:pathology; D004734:Energy Metabolism / Q000502:physiology; D004789:Enzyme Activation / Q000502:physiology; D005947:Glucose / Q000493:pharmacokinetics; D006019:Glycolysis / Q000502:physiology*; D006367:HeLa Cells; D006593:Hexokinase / Q000378:metabolism; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism / Q000473:pathology; D008954:Models, Biological; D008962:Models, Theoretical; D009369:Neoplasms / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D009994:Osmolar Concentration; D010732:Phosphofructokinase-1 / Q000378:metabolism; D014407:Tumor Cells, Cultured
D006593:Hexokinase; D010732:Phosphofructokinase-1; D005947:Glucose